GT200600023A - Combinacion de xolair con agente inmunosupresivo - Google Patents
Combinacion de xolair con agente inmunosupresivoInfo
- Publication number
- GT200600023A GT200600023A GT200600023A GT200600023A GT200600023A GT 200600023 A GT200600023 A GT 200600023A GT 200600023 A GT200600023 A GT 200600023A GT 200600023 A GT200600023 A GT 200600023A GT 200600023 A GT200600023 A GT 200600023A
- Authority
- GT
- Guatemala
- Prior art keywords
- xolair
- combination
- immunosuppressive agent
- present
- pars
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENTE UN ANTICUERPO ANTI-IGE Y AL MENOS UN AGENTE INMUNOSUPRESOR, EN DONDE LOS INGREDIENTES ACTIVOS ESTAN PRESENTES EN CADA CASO EN FORMA LIBRE O EN LA FORMA UNA SAL FARMACÉUTICAMENTE ACEPTABLE Y OPCIONALMENTE AL MENOS UN VEHICULO FARMACEUTICAMENTE ACEPTABLE, PARS USO SIMULTANEO, SEPARADO O SECUENCIAL.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0502358.5A GB0502358D0 (en) | 2005-02-04 | 2005-02-04 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
GT200600023A true GT200600023A (es) | 2006-08-16 |
Family
ID=34355808
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT200600023A GT200600023A (es) | 2005-02-04 | 2006-01-18 | Combinacion de xolair con agente inmunosupresivo |
Country Status (20)
Country | Link |
---|---|
US (1) | US20080206237A1 (es) |
EP (1) | EP1846031A1 (es) |
JP (1) | JP2008528650A (es) |
KR (1) | KR20070100344A (es) |
CN (1) | CN101111265A (es) |
AR (1) | AR053541A1 (es) |
AU (1) | AU2006210098A1 (es) |
BR (1) | BRPI0607349A2 (es) |
CA (1) | CA2595976A1 (es) |
GB (1) | GB0502358D0 (es) |
GT (1) | GT200600023A (es) |
IL (1) | IL184713A0 (es) |
MA (1) | MA29273B1 (es) |
MX (1) | MX2007009436A (es) |
NO (1) | NO20074497L (es) |
PE (1) | PE20061203A1 (es) |
RU (1) | RU2007132980A (es) |
TN (1) | TNSN07304A1 (es) |
TW (1) | TW200640487A (es) |
WO (1) | WO2006082052A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006086361A2 (en) * | 2005-02-08 | 2006-08-17 | Novartis Ag | ANTILYMPHOCYTE ANTIBODY INDUCTION BY COMBINATION OF AN SlP RECEPTOR AGONIST/MODULATOR AND OF IMMUNOSUPPRESSIVE DRUGS |
JP4954326B2 (ja) | 2008-04-11 | 2012-06-13 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
EP2853545B8 (en) * | 2008-09-17 | 2023-04-05 | Xencor, Inc. | Antibody specific for IgE |
EP2513147B1 (en) * | 2009-12-18 | 2016-07-20 | Sanofi | Novel antagonist antibodies and their fab fragments against gpvi and uses thereof |
EP4231014A3 (en) | 2010-11-30 | 2024-03-20 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
US20140093496A1 (en) | 2011-02-25 | 2014-04-03 | Chugai Seiyaku Kabushiki Kaisha | Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY |
JO3177B1 (ar) * | 2011-04-01 | 2018-03-08 | Novartis Ag | تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول |
EP2762493B1 (en) | 2011-09-30 | 2021-06-09 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
MY181199A (en) | 2014-12-19 | 2020-12-21 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
EA201791366A1 (ru) | 2014-12-19 | 2018-02-28 | Чугаи Сейяку Кабусики Кайся | Антитела к c5 и способы их применения |
CN107108729A (zh) | 2015-02-05 | 2017-08-29 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il‑8‑结合抗体,及其应用 |
BR112017014067B1 (pt) | 2015-02-27 | 2021-01-12 | Chugai Seiyaku Kabushiki Kaisha | usos de um anticorpo receptor de il-6 para no tratamento de doenças relacionadas a il-6 |
US10947320B2 (en) | 2015-12-18 | 2021-03-16 | University Of Notre Dame Du Lac | Covalent heterobivalent antibody inhibitors and ligands |
US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
GB201610198D0 (en) | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
KR20230079499A (ko) | 2016-08-05 | 2023-06-07 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
JP7191833B2 (ja) | 2017-01-30 | 2022-12-19 | 中外製薬株式会社 | 抗スクレロスチン抗体およびその使用 |
JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
DE102017215154A1 (de) | 2017-08-30 | 2019-02-28 | Markus Bläss | Zusammensetzung zur topischen Behandlung von nicht-Mikroorganismus-verursachten entzündlichen Haut- und Schleimhauterkrankungen |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6172213B1 (en) * | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
GB0200429D0 (en) * | 2002-01-09 | 2002-02-27 | Novartis Ag | Organic compounds |
-
2005
- 2005-02-04 GB GBGB0502358.5A patent/GB0502358D0/en not_active Ceased
-
2006
- 2006-01-18 GT GT200600023A patent/GT200600023A/es unknown
- 2006-02-02 CA CA002595976A patent/CA2595976A1/en not_active Abandoned
- 2006-02-02 WO PCT/EP2006/000911 patent/WO2006082052A1/en active Application Filing
- 2006-02-02 BR BRPI0607349-2A patent/BRPI0607349A2/pt not_active Application Discontinuation
- 2006-02-02 MX MX2007009436A patent/MX2007009436A/es not_active Application Discontinuation
- 2006-02-02 PE PE2006000134A patent/PE20061203A1/es not_active Application Discontinuation
- 2006-02-02 EP EP06706581A patent/EP1846031A1/en not_active Withdrawn
- 2006-02-02 CN CNA2006800039151A patent/CN101111265A/zh active Pending
- 2006-02-02 RU RU2007132980/13A patent/RU2007132980A/ru not_active Application Discontinuation
- 2006-02-02 US US11/814,871 patent/US20080206237A1/en not_active Abandoned
- 2006-02-02 KR KR1020077017947A patent/KR20070100344A/ko not_active Application Discontinuation
- 2006-02-02 AU AU2006210098A patent/AU2006210098A1/en not_active Abandoned
- 2006-02-02 AR ARP060100378A patent/AR053541A1/es not_active Application Discontinuation
- 2006-02-02 JP JP2007553536A patent/JP2008528650A/ja active Pending
- 2006-02-03 TW TW095103825A patent/TW200640487A/zh unknown
-
2007
- 2007-07-19 IL IL184713A patent/IL184713A0/en unknown
- 2007-08-03 TN TNP2007000304A patent/TNSN07304A1/en unknown
- 2007-08-28 MA MA30171A patent/MA29273B1/fr unknown
- 2007-09-04 NO NO20074497A patent/NO20074497L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2006210098A1 (en) | 2006-08-10 |
KR20070100344A (ko) | 2007-10-10 |
EP1846031A1 (en) | 2007-10-24 |
TW200640487A (en) | 2006-12-01 |
GB0502358D0 (en) | 2005-03-16 |
TNSN07304A1 (en) | 2008-12-31 |
MX2007009436A (es) | 2007-08-17 |
PE20061203A1 (es) | 2006-12-19 |
US20080206237A1 (en) | 2008-08-28 |
BRPI0607349A2 (pt) | 2009-09-01 |
CA2595976A1 (en) | 2006-08-10 |
CN101111265A (zh) | 2008-01-23 |
WO2006082052A1 (en) | 2006-08-10 |
AR053541A1 (es) | 2007-05-09 |
IL184713A0 (en) | 2007-12-03 |
NO20074497L (no) | 2007-10-26 |
MA29273B1 (fr) | 2008-02-01 |
RU2007132980A (ru) | 2009-03-10 |
JP2008528650A (ja) | 2008-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT200600023A (es) | Combinacion de xolair con agente inmunosupresivo | |
GT199900203A (es) | Composiciones de celecoxib. | |
ECSP077999A (es) | Formulaciones de una sal de bupropion de liberación modificada | |
CR8428A (es) | Agente endoparasiticidas para la administracion topica | |
ECSP066346A (es) | Forma de administración a prueba de abuso | |
ECSP078057A (es) | Formulaciones de estrógenos conjugados y bazedoxifeno | |
UY28509A1 (es) | Formas de dosificacion de azitromicina con efectos secundarios reducidos | |
CU20120080A7 (es) | Formulaciones de anticuerpo | |
PA8493401A1 (es) | Uso de inhibidores de cyp2d6 en terapias de combinacion | |
AR061348A1 (es) | Preparados estables de laquinimod | |
WO2004089396A3 (en) | Anti-fungal peptidomimetics | |
AR018109A1 (es) | FORMULACIoN GALÉNICA ADMINISTRABLE POR VíA ORAL QUE PERMITE UNA ABSORCIoN MEJORADA DE PRINCIPIOS ACTIVOS, USO DE UN AGENTE MAJORADOR DE ABSORCIoN PARA PREPARAR UNA FORMA DE DOSIFICACIoN ADMINISTRABLE POR VíA ORAL Y PROCEDIMIENTO PARA PREPARAR DICHA FORMULACIoN GALÉNICA | |
TR201908551T4 (tr) | Yakıt bileşimleri. | |
AR034900A1 (es) | Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica | |
GT200800107A (es) | Formulaciones orales que comprenden tigeciclina | |
CL2007001752A1 (es) | Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral. | |
NO20073026L (no) | 2-alkoksy-3,4,5-trihydroksy-alkylamider, fremstilling og sammensetninger derav samt anvendelse derav | |
UY27727A1 (es) | Nueva composicion farmacéutica- | |
BR0113148A (pt) | Composições de 2-piridinamina e métodos relacionados | |
EA200702496A1 (ru) | Местная композиция, содержащая желатин | |
EA200970353A1 (ru) | Комбинированное лекарственное средство | |
AR052048A1 (es) | Composiciones farmaceuticas para el tratamiento de la celulitis | |
AR038560A1 (es) | Una composicion antitranspirante/ desodorante | |
AR065068A1 (es) | Composicion farmaceutica que comprende tramadol y ketoprofeno en asociacion | |
SE0001440D0 (sv) | A drug against climacteric disorders |